AU2005307765C1 - Roles for Dual Endothelin-1/Angiotensin II Receptor (DEAR) in hypertension and angiogenesis - Google Patents

Roles for Dual Endothelin-1/Angiotensin II Receptor (DEAR) in hypertension and angiogenesis Download PDF

Info

Publication number
AU2005307765C1
AU2005307765C1 AU2005307765A AU2005307765A AU2005307765C1 AU 2005307765 C1 AU2005307765 C1 AU 2005307765C1 AU 2005307765 A AU2005307765 A AU 2005307765A AU 2005307765 A AU2005307765 A AU 2005307765A AU 2005307765 C1 AU2005307765 C1 AU 2005307765C1
Authority
AU
Australia
Prior art keywords
dahl
antibody
angiogenesis
hypertension
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005307765A
Other languages
English (en)
Other versions
AU2005307765A1 (en
AU2005307765A2 (en
AU2005307765B8 (en
AU2005307765B2 (en
Inventor
Victoria L.M. Herrera
Nelson Ruiz-Opazo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of AU2005307765A1 publication Critical patent/AU2005307765A1/en
Publication of AU2005307765A2 publication Critical patent/AU2005307765A2/en
Application granted granted Critical
Publication of AU2005307765B2 publication Critical patent/AU2005307765B2/en
Publication of AU2005307765B8 publication Critical patent/AU2005307765B8/en
Priority to AU2011202881A priority Critical patent/AU2011202881B2/en
Publication of AU2005307765C1 publication Critical patent/AU2005307765C1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
AU2005307765A 2004-11-16 2005-11-15 Roles for Dual Endothelin-1/Angiotensin II Receptor (DEAR) in hypertension and angiogenesis Expired AU2005307765C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202881A AU2011202881B2 (en) 2004-11-16 2011-06-16 Roles for dual endothelin-1/angiotensin II receptor (DEAR) in hypertension and angiogenesis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62844704P 2004-11-16 2004-11-16
US60/628,447 2004-11-16
US69426805P 2005-06-27 2005-06-27
US60/694,268 2005-06-27
PCT/US2005/041594 WO2006055665A2 (en) 2004-11-16 2005-11-15 Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202881A Division AU2011202881B2 (en) 2004-11-16 2011-06-16 Roles for dual endothelin-1/angiotensin II receptor (DEAR) in hypertension and angiogenesis

Publications (5)

Publication Number Publication Date
AU2005307765A1 AU2005307765A1 (en) 2006-05-26
AU2005307765A2 AU2005307765A2 (en) 2006-05-26
AU2005307765B2 AU2005307765B2 (en) 2011-04-21
AU2005307765B8 AU2005307765B8 (en) 2011-05-12
AU2005307765C1 true AU2005307765C1 (en) 2012-07-05

Family

ID=36407731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005307765A Expired AU2005307765C1 (en) 2004-11-16 2005-11-15 Roles for Dual Endothelin-1/Angiotensin II Receptor (DEAR) in hypertension and angiogenesis

Country Status (6)

Country Link
US (3) US7919093B2 (enExample)
EP (2) EP1812473A4 (enExample)
JP (2) JP5341350B2 (enExample)
AU (1) AU2005307765C1 (enExample)
CA (1) CA2588066A1 (enExample)
WO (1) WO2006055665A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
PH12012501070A1 (en) * 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US20130022551A1 (en) * 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP3341413A4 (en) 2015-08-24 2019-07-17 Trustees of Boston University THERAPY AND IMAGING FOR CANCER AND STROKE ON MONOCLONAL ANTI-DESPR ANTIBODIES
JP7404230B2 (ja) 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
WO2019241609A1 (en) 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
WO2022081792A1 (en) 2020-10-15 2022-04-21 Trustees Of Boston University Antibody therapies and methods for treating coronavirus infection
CN116530469B (zh) * 2023-07-06 2023-09-19 首都医科大学 腹主动脉瘤动物模型的制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
CA2134552A1 (en) 1992-04-27 1993-11-11 George D. Sorenson Detection of gene sequences in biological fluids
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
WO1997040462A2 (en) 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
EP0979869A1 (en) 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Short oligonucleotides for the inhibition of VEGF expression
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression

Also Published As

Publication number Publication date
EP2194144A1 (en) 2010-06-09
AU2005307765A1 (en) 2006-05-26
EP2194144B1 (en) 2015-01-07
AU2005307765A2 (en) 2006-05-26
EP1812473A4 (en) 2009-12-23
AU2005307765B8 (en) 2011-05-12
CA2588066A1 (en) 2006-05-26
JP5341350B2 (ja) 2013-11-13
JP2012233000A (ja) 2012-11-29
AU2005307765B2 (en) 2011-04-21
WO2006055665A2 (en) 2006-05-26
JP2008520241A (ja) 2008-06-19
US20090028852A1 (en) 2009-01-29
US7919093B2 (en) 2011-04-05
US8956609B2 (en) 2015-02-17
US20110142821A1 (en) 2011-06-16
EP1812473A2 (en) 2007-08-01
WO2006055665A3 (en) 2009-04-09
US20140186344A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
US8956609B2 (en) Roles for Dual Endothelin-1/Angiotensin II Receptor (Dear) in hypertension and angiogenesis
AU2020201633B2 (en) Methods for inhibiting angiogenesis in a subject in need thereof
KR102014066B1 (ko) 항 α-syn 항체 및 그 용도
EP2970470B1 (en) Human pac1 antibodies
EA016193B1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их использования
AU2017205453A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
KR20170044691A (ko) 염증을 치료 및 예방하기 위한 조성물 및 방법
KR20140138215A (ko) 신규 항 Ｓｉｇｌｅｃ-15 항체
JP7125979B2 (ja) 異所性骨化の治療又は予防のための医薬組成物
WO2018217688A1 (en) Compositions and methods for inhibition of mica/b shedding
KR20190085935A (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
JP2025121919A (ja) アイソフォーム選択的抗ｔｇｆ－ベータ抗体及び使用方法
AU2011202881B2 (en) Roles for dual endothelin-1/angiotensin II receptor (DEAR) in hypertension and angiogenesis
WO2007083759A1 (ja) 抗ｃｃｌ２０抗体を含む骨破壊抑制剤
WO2005107799A1 (ja) 抗Necl-5抗体を有効成分として含む癌治療剤
RU2839151C1 (ru) Селективные в отношении изоформы антитела к tgf-бета и способы их применения
JP2004500872A (ja) Ｇｐ３５４核酸およびポリペプチド
HK40100980A (en) Methods for inhibiting angiogenesis in a subject in need thereof
HK40081861A (en) Methods for inhibiting angiogenesis in a subject in need thereof
HK40034384A (en) Pharmaceutical composition for treating or preventing heterotopic ossification

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 MAY 2007

TH Corrigenda

Free format text: IN VOL 25, NO 16, PAGE(S) 1982 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME TRUSTEES OF BOSTON UNIVERSITY, APPLICATION NO. 2005307765, UNDER INID (54) CORRECT THE TITLE TO READ ROLES FOR DUAL ENDOTHELIN-/1ANGIOTENSIN II RECEPTOR (DEAR) IN HYPERTENSION AND ANGIOGENESIS

TH Corrigenda

Free format text: IN VOL 25, NO 16, PAGE(S) 1982 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME TRUSTEES OF BOSTON UNIVERSITY, APPLICATION NO. 2005307765, UNDER INID (54) CORRECT THE TITLE TO READ ROLES FOR DUAL ENDOTHELIN-1/ANGIOTENSIN II RECEPTOR (DEAR) IN HYPERTENSION AND ANGIOGENESIS

Free format text: IN VOL 25, NO 18, PAGE(S) 2323 UNDER THE HEADING CORRIGENDA DELETE ALL REFERENCE TO 2005307765

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2012

MK14 Patent ceased section 143(a) (annual fees not paid) or expired